New discovery may lead the way to improved whooping cough vaccine

May 13, 2013

Scientists at Trinity College Dublin have made novel discoveries concerning the current vaccine against whooping cough that may lead to the development of an improved future vaccine. The findings could help reduce the incidence of the disease which is increasing in developed countries. The research led by Professor of Experimental Immunology, Kingston Mills has just been published in the leading international journal PloS Pathogens.

A new against whooping cough, caused by the bacteria Bordetella pertussis was first introduced to the routine vaccination schedule for infants and children in most developed countries, including Ireland over a decade ago. Prior to the introduction of this vaccine, children were immunised with a vaccine made from whole bacteria. Although this 'whole cell ' was effective at preventing the infection, it had been associated with side effects. Dissatisfaction with that vaccine led to the development of an 'acellular pertussis vaccine' made from components of the bacteria combined with an to boost immune responses. Following its introduction in the late 1990s, the new vaccine has proved to be very safe and has been effective in controlling the potentially fatal disease of whooping cough in children. However, protective immunity conferred with the vaccine falls quite quickly, necessitating frequent booster vaccinations. This fall off in the immunity may be contributing to the number of whooping cough cases which are increasing with quite dramatic increases reported in certain countries, including the US, Australia and the Netherlands.

Professor Kingston Mills's research team at the School of Biochemistry and Immunology in the Trinity Biomedical Sciences Institute has discovered important mechanistic differences in the type of immune responses induced with the new 'acellular' and old 'whole cell' vaccine. The whole cell vaccine, although much more likely to cause in recipients, was capable of inducing strong cellular immune responses mediated by white blood cells called T cells, in particular a type of T cell called Th1 cells. In contrast, the new acellular vaccine, although safer, was less effective in inducing cellular immunity, but instead induced immunity mediated by antibodies and another type of T cell called a Th17 cell.

Most vaccines include a component called an adjuvant to boost immune responses to the bacterial or viral antigens in the vaccine and the acellular pertussis vaccine uses an aluminium salt, called alum. However, Dr Padraig Ross, Dr Sarah Higgins and Ms Aideen Allen in Professor Mills' laboratory, working in collaboration with Dr Rachel McLoughlin and Dr Ed Lavelle, have shown that the vaccine could be improved further through the use of a different adjuvant.

The current vaccine does not enhance the induction of Th1 cells, required for conferring optimum against the bacteria. They showed that by switching the adjuvant from alum to an adjuvant based on bacterial DNA, they could induce the crucial Th1 cells and thereby enhance the efficacy of the vaccine against infection in a murine model. The new vaccine has the potential to protect a higher proportion of immunised children using a lower number of doses.

Commenting on the significance of the findings, Professor Mills said:

"Although it will not be an easy task to implement, our findings should pave the way for an improved vaccine against in children."

The finding from Science Foundation Ireland-funded TCD research was published online last week in the leading peer-review journal PloS Pathogens. The challenges with the current pertussis vaccine will be a central theme of the 10th International symposium on Bordetella being organised by Professor Mills in Trinity College Dublin in September of this year.

Explore further: Researcher says whooping cough vaccines effective, despite outbreaks

Related Stories

Researcher says whooping cough vaccines effective, despite outbreaks

November 29, 2012
(Medical Xpress)—Despite recent outbreaks of pertussis (whooping cough)—a highly contagious bacterial disease that is preventable by the current pertussis vaccines—Yale researcher Dr. Eugene Shapiro maintains in an ...

Vaccine fails to protect babies against whooping cough

August 1, 2012
(Medical Xpress) -- Queensland research shows that a resurgence of whooping cough in babies has arisen due to the lack of effectiveness of the current vaccine.

More evidence whooping cough protection wanes

March 11, 2013
(HealthDay)—Despite high levels of vaccination, the rate of whooping cough in the United States is at its highest level in decades, and one reason may be that immunity from the vaccine diminishes each year after the fifth ...

Protection against whooping cough waned during the five years after fifth dose of DTaP

September 12, 2012
OAKLAND, Calif. − Protection against whooping cough (also called pertussis) waned during the five years after the fifth dose of the combined diphtheria, tetanus, acellular pertussis (DTaP) vaccine, according to researchers ...

Findings support safety of whooping cough vaccine for older adults

November 29, 2012
A new study of the safety of the tetanus-diphtheria-acellular pertussis (Tdap) vaccine supports the recommendation that those 65 and older get the vaccine to protect themselves and others, particularly young babies, from ...

CDC panel: all pregnant women should get whooping cough shot

October 24, 2012
(HealthDay)—All pregnant women should be vaccinated against pertussis, also known as whooping cough, preferably in their last trimester, a panel of U.S. advisers recommended Wednesday.

Recommended for you

Pneumonia vaccine under development provides 'most comprehensive coverage' to date, alleviates antimicrobial concerns

October 20, 2017
In 2004, pneumonia killed more than 2 million children worldwide, according to the World Health Organization. By 2015, the number was less than 1 million.

Newly discovered viral marker could help predict flu severity in infected patients

October 20, 2017
Flu viruses contain defective genetic material that may activate the immune system in infected patients, and new research published in PLOS Pathogens suggests that lower levels of these molecules could increase flu severity.

H7N9 influenza is both lethal and transmissible in animal model for flu

October 19, 2017
In 2013, an influenza virus that had never before been detected began circulating among poultry in China. It caused several waves of human infection and in late 2016, the number of people to become sick from the H7N9 virus ...

Flu simulations suggest pandemics more likely in spring, early summer

October 19, 2017
New statistical simulations suggest that Northern Hemisphere flu pandemics are most likely to emerge in late spring or early summer at the tail end of the normal flu season, according to a new study published in PLOS Computational ...

New insights into herpes virus could inform vaccine development

October 18, 2017
A team of scientists has discovered new insights into the mechanisms of Epstein-Barr virus (EBV) infection, as well as two antibodies that block the virus' entry into cells. The findings, published in Proceedings of the National ...

Pair of discoveries illuminate new paths to flu and anthrax treatments

October 17, 2017
Two recent studies led by biologists at the University of California San Diego have set the research groundwork for new avenues to treat influenza and anthrax poisoning.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.